Matthew Barajas

Dr. Matthew Barajas

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MZMichael Zargari
Michael Zargari
LMLuise J. Meyer
Luise J. Meyer
Matthias RiessMatthias Riess
Matthias Riess
ZLZhu Li
Zhu Li
MBMatthew Barajas
Matthew Barajas
Traumatic brain injury (TBI) is a significant cause of morbidity and mortality worldwide. Varied mechanisms of injury contribute to the heterogeneity of this patient population as demonstrated by the multiple published grading scales and diverse required criteria leading to diagnoses from mild to severe. TBI pathophysiology is classically separated into a primary injury that is characterized by local tissue destruction as a result of the initial blow, followed by a secondary phase of injury constituted by a score of incompletely understood cellular processes including reperfusion injury, disruption to the blood-brain barrier, excitotoxicity, and metabolic dysregulation. There are currently no effective pharmacological treatments in the wide-spread use for TBI, in large part due to challenges associated with the development of clinically representative in vitro and in vivo models. Poloxamer 188 (P188), a Food and Drug Administration-approved amphiphilic triblock copolymer embeds itself into the plasma membrane of damaged cells. P188 has been shown to have neuroprotective properties on various cell types. The objective of this review is to provide a summary of the current literature on in vitro models of TBI treated with P188.

14 April 2023 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
MBMatthew Barajas
Matthew Barajas
MRMatthias L. Riess
Matthias L. Riess
MHMatthew J. W. Hampton
Matthew J. W. Hampton
ZLZhu Li
Zhu Li
YSYaping Shi
Yaping Shi
SESusan S. Eagle
Susan S. Eagle
BACKGROUND: Early detection and quantification of perioperative hemorrhage remains challenging. Peripheral intravenous waveform analysis (PIVA) is a novel method that uses a standard intravenous catheter to detect interval hemorrhage. We hypothesize that subclinical blood loss of 2% of the estimated blood volume (EBV) in a rat model of hemorrhage is associated with significant changes in PIVA. Secondarily, we will compare PIVA association with volume loss to other static, invasive, and dynamic markers. METHODS: Eleven male Sprague Dawley rats were anesthetized and mechanically ventilated. A total of 20% of the EBV was removed over ten 5 minute-intervals. The peripheral intravenous pressure waveform was continuously transduced via a 22-G angiocatheter in the saphenous vein and analyzed using MATLAB. Mean arterial pressure (MAP) and central venous pressure (CVP) were continuously monitored. Cardiac output (CO), right ventricular diameter (RVd), and left ventricular end-diastolic area (LVEDA) were evaluated via transthoracic echocardiogram using the short axis left ventricular view. Dynamic markers such as pulse pressure variation (PPV) were calculated from the arterial waveform. The primary outcome was change in the first fundamental frequency (F1) of the venous waveform, which was assessed using analysis of variance (ANOVA). Mean F1 at each blood loss interval was compared to the mean at the subsequent interval. Additionally, the strength of the association between blood loss and F1 and each other marker was quantified using the marginal R 2 in a linear mixed-effects model. RESULTS: PIVA derived mean F1 decreased significantly after hemorrhage of only 2% of the EBV, from 0.17 to 0.11 mm Hg, P = .001, 95% confidence interval (CI) of difference in means 0.02 to 0.10, and decreased significantly from the prior hemorrhage interval at 4%, 6%, 8%, 10%, and 12%. Log F1 demonstrated a marginal R 2 value of 0.57 (95% CI 0.40–0.73), followed by PPV 0.41 (0.28–0.56) and CO 0.39 (0.26–0.58). MAP, LVEDA, and systolic pressure variation displayed R 2 values of 0.31, and the remaining predictors had R 2 values ≤0.2. The difference in log F1 R 2 was not significant when compared to PPV 0.16 (95% CI −0.07 to 0.38), CO 0.18 (−0.06 to 0.04), or MAP 0.25 (−0.01 to 0.49) but was significant for the remaining markers. CONCLUSIONS: The mean F1 amplitude of PIVA was significantly associated with subclinical blood loss and most strongly associated with blood volume among the markers considered. This study demonstrates feasibility of a minimally invasive, low-cost method for monitoring perioperative blood loss.

17 June 2024 in Cells
Verified
Journal Article
Open access
PDF file
MBMatthew Barajas
Matthew Barajas
TOTakuro Oyama
Takuro Oyama
MSMasakazu Shiota
Masakazu Shiota
ZLZhu Li
Zhu Li
MZMaximillian Zaum
Maximillian Zaum
Matthias RiessMatthias Riess
Matthias Riess
Background: Ischemic post-conditioning (IPoC) has been shown to improve outcomes in limited pre-clinical models. As down-time is often unknown, this technique needs to be investigated over a range of scenarios. As this tool limits reperfusion injury, there may be limited benefit or even harm after short arrest and limited ischemia-reperfusion injury. Methods: Eighteen male Wistar rats underwent 7 min of asphyxial arrest. Animals randomized to IPoC received a 20 s pause followed by 20 s of compressions, repeated four times, initiated 40 s into cardiopulmonary resuscitation. If return of spontaneous circulation (ROSC) was achieved, epinephrine was titrated to mean arterial pressure (MAP) of 70 mmHg. Data were analyzed using t-test or Mann–Whitney test. Significance set at p ≤ 0.05. Results: The rate of ROSC was equivalent in both groups, 88%. There was no statistically significant difference in time to ROSC, epinephrine required post ROSC, carotid flow, or peak lactate at any timepoint. There was a significantly elevated MAP with IPoC, 90.7 mmHg (SD 13.9), as compared to standard CPR, 76.7 mmHg (8.5), 2 h after ROSC, p = 0.03. Conclusions: IPoC demonstrated no harm in a model of short arrest using a new arrest etiology for CPR based IPoC intervention in a rat model.

15 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
ZLZhu Li
Zhu Li
MGMukesh K. Gupta
Mukesh K. Gupta
MBMatthew Barajas
Matthew Barajas
TOTakuro Oyama
Takuro Oyama
CDCraig Duvall
Craig Duvall
Matthias RiessMatthias Riess
Matthias Riess
Reperfusion after ischemia causes additional cellular damage, known as reperfusion injury, for which there is still no effective remedy. Poloxamer (P)188, a tri-block copolymer-based cell membrane stabilizer (CCMS), has been shown to provide protection against hypoxia/reoxygenation (HR) injury in various models by reducing membrane leakage and apoptosis and improving mitochondrial function. Interestingly, substituting one of its hydrophilic poly-ethylene oxide (PEO) blocks with a (t)ert-butyl terminus added to the hydrophobic poly-propylene oxide (PPO) block yields a di-block compound (PEO-PPOt) that interacts better with the cell membrane lipid bi-layer and exhibits greater cellular protection than the gold standard tri-block P188 (PEO75-PPO30-PEO75). For this study, we custom-made three different new di-blocks (PEO113-PPO10t, PEO226-PPO18t and PEO113-PPO20t) to systemically examine the effects of the length of each polymer block on cellular protection in comparison to P188. Cellular protection was assessed by cell viability, lactate dehydrogenase release, and uptake of FM1-43 in mouse artery endothelial cells (ECs) following HR injury. We found that di-block CCMS were able to provide the same or better EC protection than P188. Our study provides the first direct evidence that custom-made di-block CCMS can be superior to P188 in improving EC membrane protection, raising their potential in treating cardiac reperfusion injury.

4 March 2022 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
MBMatthew Barajas
Matthew Barajas
RLRichard J. Levy
Richard J. Levy
The use of the ex-vivo retrograde perfused heart has long been a cornerstone of ischemia-reperfusion investigation since its development by Oskar Langendorff over a century ago. Although this technique has been applied to mice over the last 25 years, its use in this species has been limited to adult animals. Development of a successful method to consistently cannulate the neonatal murine aorta would allow for the systematic study of the isolated retrograde perfused heart during a critical period of cardiac development in a genetically modifiable and low-cost species. Modification of the Langendorff preparation enables cannulation and establishment of reperfusion in the neonatal murine heart while minimizing ischemic time. Optimization requires a two-person technique to permit successful cannulation of the newborn mouse aorta using a dissecting microscope and a modified commercially available needle. The use of this approach will reliably establish retrograde perfusion within 3 min. Because the fragility of the neonatal mouse heart and ventricular cavity size prevents direct measurement of intraventricular pressure generated using a balloon, use of a force transducer connected by a suture to the apex of the left ventricle to quantify longitudinal contractile tension is necessary. This method allows investigators to successfully establish an isolated constant-flow retrograde-perfused newborn murine heart preparation, permitting the study of developmental cardiac biology in an ex-vivo manner. Importantly, this model will be a powerful tool to investigate the physiological and pharmacological responses to ischemia-reperfusion in the neonatal heart.

Verified
Journal Article
Open access
PDF file
MWMiriam Walter
Miriam Walter
MSMasakazu Shiota
Masakazu Shiota
ZLZhu Li
Zhu Li
MBMatthew Barajas
Matthew Barajas
TOTakuro Oyama
Takuro Oyama
Matthias RiessMatthias Riess
Matthias Riess
The rising prevalence of type 2 diabetes is linked to an increased risk of cardiovascular diseases, with the diabetic heart being particularly vulnerable to ischemia–reperfusion (IR) injury. Chronic hyperglycemia contributes to an increase in reactive oxygen species and impacts the homeostasis of biochemical pathways, including the polyol pathway, increasing susceptibility to damage. Aldose reductase (AR), a key enzyme in this pathway, has been targeted for therapeutic intervention, with AR inhibitors showing potential in mitigating diabetic complications. This study investigated IR injury in cardiomyocytes following high glucose exposure and assessed the AR inhibitor Epalrestat as a protective agent. Cardiomyocyte function was evaluated by measuring lactate dehydrogenase (LDH) release, FM1-43 membrane incorporation, cell viability, intracellular calcium accumulation, and superoxide anion formation. High glucose exposure and simulated IR led to increased LDH release, FM1-43 incorporation, intracellular calcium, and superoxide levels, alongside reduced cell viability in a dose-dependent manner. However, Epalrestat treatment during high glucose exposure significantly reduced IR-induced injury. These findings suggest that high glucose exacerbates IR injury in cardiomyocytes, with the polyol pathway playing a critical role. Targeting this pathway with AR inhibitors like Epalrestat may offer a protective strategy against diabetic heart complications.